ChemoCentryx, Inc. (CCXI) is a small-cap biopharmaceutical company developing new chemokine and chemoattractant systems and medications for inflammatory and autoimmune diseases and cancer. The company’s current focus is on its late stage drug candidates for patients with rare diseases CCX168 and CCX140. CCX168, trade named avacopan, is an orally administered small molecule, which is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in phase 3 development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated Vasculitis or AAV). The drug is also being developed for other indications. The U.S.